Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
about
Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceOutcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysisSystematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?Financial Impact of Direct-Acting Oral Anticoagulants in Medicaid: Budgetary Assessment Based on Number Needed to Treat.Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia.Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.A Guide to the Economics of Hepatitis C Virus Cure in 2017
P2860
Q28072257-03F1CC47-FD9A-4713-9145-65910AFE447DQ30376341-53906970-EB83-4C76-A663-ECB88F859156Q36238515-229DD47F-BF1A-4B19-A98E-0BD38799F0F2Q36479439-99070C9D-D2CE-418B-8662-6D824A1534C1Q37735902-61A5B09B-FADD-47F9-8393-B5D9851BE388Q38691333-B3D8BAAF-189C-4D85-A259-DCE12A27CD2AQ38996459-EA21D8F1-5970-4882-916F-954C59DA422FQ39146511-B664371F-1303-4CFC-9769-6A28B1A28DA0Q40072613-661FEBBB-2BE0-4BD4-9970-4F2E55D03742Q40420373-15E7531B-6E34-47DD-8581-814ECD527D65Q40562865-037CEBEA-ADC0-4EED-B897-55FFAF40B0C5Q40576603-221FD983-933D-4F1B-A6EA-FF64B9222C47Q40677384-8BA79271-DE39-422D-BE6F-0C9125D8B199Q40720905-BA83A877-BEAD-4D36-831E-95E0B3E6DA16Q42048758-B2336158-4328-4555-AB52-1209C47F906AQ42373161-0A45FFEA-8915-4B78-8FFE-5BEDF27F91ABQ44781142-143E1AE7-1025-442E-AFE5-EED7D4A82F54Q47559564-E95E389C-46D2-4B85-A1FA-327D797A1B13Q52653977-41114121-5F69-4392-ABF7-B05374D0EF7DQ53381076-925D3AA6-3996-44FB-9E01-70681F0F3C94Q54984374-1D773BB3-D962-4FD2-BA30-8C24CBD414B9Q55280669-F0E93A9D-B731-49E9-AC07-8EE61E0C0274Q56654943-4786EA27-D36F-4A8C-9144-F1858DE58C25
P2860
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
@ast
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
@en
type
label
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
@ast
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
@en
prefLabel
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
@ast
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
@en
P2093
P2860
P1433
P1476
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
@en
P2093
Nathaniel D Bastian
Paul M Griffin
P2860
P2888
P356
10.1186/S12876-015-0320-4
P577
2015-08-05T00:00:00Z
P5875
P6179
1050959154